HSV Strain |
Genetic Modification |
Therapeutic Transgenes |
Clinical Indications |
Ref. |
Replication-Competent Vectors |
NV1020 (HSV-1) |
Deletion in one copy of ICP34.5 + tk under ICP4 promoter control + deletion in UL24, 55 and 56 |
none |
Anti HSV vaccine |
[121, 122] |
RAV9395 (HSV-2) |
Deletion in both copy of ICP34.5 + deletion in UL55 and 56 + deletion in both copy of ORF P |
none |
Anti HSV vaccine |
[118] |
AD-472 (HSV-2) |
Deletion in both copy of ICP34.5 + deletion in UL55 and 56 + deletion in both copy of ORF P + deletion of UL43.5 + deletion of US10-12 |
none |
Anti HSV vaccine |
[126, 127] |
NS-gEnull (HSV-1) |
Deletion of US8 |
none |
Anti HSV vaccine |
[128] |
ImmunoVEXHSV2
|
Deletion of genes involved in immune evasion |
none |
Anti HSV vaccine |
www.biovex.com |
Replication-Defective Vectors |
dl5-29 (HSV-2) |
Deletion of UL5 and 29 |
none |
Anti HSV vaccine |
[99, 103, 105] |
dl5-29-41L (HSV-2) |
Deletion of UL5 and 29 + deletion of UL41 |
none |
Anti HSV vaccine |
[99, 104, 105] |
DISC-gH (HSV-1) |
Deletion of gH |
none |
Anti HSV vaccine |
[101, 106] |
DISC gH (HSV-2) |
Deletion of gH |
mGM-CSF or hIL-12 |
Anti HSV vaccine and anti tumour vaccine |
[108, 109] |
CJ9gD (HSV-1) |
Deletion of UL9 |
Over-expression of gD |
Anti HSV vaccine |
[110-112] |
TOH-OVA (HSV-1) |
Deletion of ICP4, 22, 27, and 47 |
Ovalbumin |
Anti bacterial infections |
[94] |
d106 (HSV-1) |
Deletion of ICP4, 22, and 27 |
HIV-1 Tat |
Anti HIV vaccine |
[114] |
d81 (HSV-1) |
Deletion of ICP27 |
SIV Env and Nef |
Anti SIV vaccine |
[115] |
HSV-SIV d106 (HSV-1) |
Deletion of ICP4, 22, 27, and 47 |
SIV Gag, Env, and Tat-Rev-Nef fusion protein |
Anti SIV vaccine |
[95, 116] |
d106S (HSV-1) |
Deletion of ICP4, 22, 27, and 47 + increased acyclovir resistance |
HIV-1 Tat |
Anti HIV vaccine |
[117] |